{"id":"NCT03271021","sponsor":"Vyne Therapeutics Inc.","briefTitle":"A Study to Evaluate the Efficacy and Safety of Topical Administration of FMX101 in the Treatment of Moderate-to-Severe Acne Vulgaris","officialTitle":"A Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Efficacy and Safety of Topical Administration of FMX101 for 12 Weeks in the Treatment of Moderate-to-Severe Acne Vulgaris (Study FX2017-22)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-07-17","primaryCompletion":"2018-09-04","completion":"2018-09-04","firstPosted":"2017-09-01","resultsPosted":"2020-02-21","lastUpdate":"2022-01-18"},"enrollment":1488,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Acne Vulgaris"],"interventions":[{"type":"DRUG","name":"FMX101","otherNames":[]},{"type":"DRUG","name":"Vehicle Foam","otherNames":[]}],"arms":[{"label":"FMX101, 4% minocycline foam","type":"EXPERIMENTAL"},{"label":"Vehicle foam","type":"PLACEBO_COMPARATOR"}],"summary":"A Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Efficacy and Safety of Topical Administration of FMX101 for 12 Weeks in the Treatment of Moderate-to-Severe Acne Vulgaris (Study FX2017-22)","primaryOutcome":{"measure":"The Absolute Change From Baseline in the Inflammatory Lesion Count at Week 12.","timeFrame":"12 weeks","effectByArm":[{"arm":"FMX101, 4% Minocycline Foam","deltaMin":16.39,"sd":null},{"arm":"Vehicle Foam","deltaMin":12.74,"sd":null}],"pValues":[]},"eligibility":{"minAge":"9 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":98,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":["http://foamix.co.il/"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":737},"commonTop":[]}}